Dade Behring’s 8% January Stock Advance Builds On 129% Leap In 2003
This article was originally published in The Gray Sheet
Executive Summary
Dade Behring's focus on growing its clinical lab diagnostics business while reducing debt, combined with a rising profile on Wall Street and plans to enter the high-volume testing category, are buoying the firm's stock price